DDInter154 DDInter1343
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
Opicapone is a potent, reversible, and peripherally-acting third-generation inhibitor of catechol-o-methyltransferase (COMT), an enzyme involved in the breakdown of various catecholamines including dopamine.[A36938, A203048] Many patients with Parkinson’s disease treated with levodopa plus a dopa decarboxylase (DDC) inhibitor (eg carbidopa) experience motor complications over time, which calls for the management of these symptoms through the use of a dopamine agonist, a monoamine oxidase B inhibitor (selegiline, rasagiline), a _catechol-O-methyl transferase (COMT)_ inhibitor, or amantadine, or using a modified-release formulation of levodopa. Opicapone is used for adjunct therapy to levodopa and carbidopa in adult patients with Parkinson's disease and end-of-dose motor fluctuations. Opicapone was approved for use by the European Commission in June 2016 and the FDA in April 2020. It is marketed under the brand name Ongentys as once-daily oral capsules. Exhibiting a long duration of action that exceeds 24 hours, opicapone can be administered once-daily and demonstrates the lowest risk for cytotoxicity compared to other catechol-O-methyltransferase inhibitors.
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Prazepam
Prazepam {u} (Compound) resembles {v} (Compound) Methdilazine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Clemastine
Clemastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methdilazine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) binds {v} (Gene) HRH1
HRH1 {u} (Gene) is bound by {v} (Compound) Methdilazine
Methdilazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Chlorcyclizine {u} (Compound) resembles {v} (Compound) Phenindamine
Phenindamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Azatadine
Azatadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) upregulates {v} (Gene) PROS1
PROS1 {u} (Gene) is upregulated by {v} (Compound) Cyclizine
Cyclizine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Morphine
Morphine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine {u} (Compound) downregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Cyclizine
Cyclizine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Opicapone
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Prazepam (Compound) and Prazepam (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Clemastine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Phenindamine (Compound) and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Azatadine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) upregulates PROS1 (Gene) and PROS1 (Gene) is upregulated by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone
Azelastine (Compound) downregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Cyclizine (Compound) and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone